Navelbine Oral (Vinorelbine)

Vinorelbine is employed in oncology to interfere with cell division in solid tumours. It is indicated for the following conditions:

• Non‑small cell lung cancer: improves disease control and prolongs survival when used in combination regimens.
• Breast cancer: used as part of combination chemotherapy to reduce tumour burden.
• Metastatic solid tumours (selected): provides therapeutic benefit in patients for whom other options are limited.

• Vinorelbine binds to the tubulin protein within cells, preventing microtubule polymerisation. This disruption blocks the formation of the mitotic spindle, arresting cell division in the M phase and leading to apoptosis of rapidly proliferating cancer cells.

Vinorelbine may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects

• Nausea: mild to moderate upset stomach.
• Vomiting: occasional episodes after dosing.
• Neutropenia: reduced white blood cell count.
• Anemia: lowered red blood cell levels.
• Constipation: decreased bowel movements.
• Fatigue: general tiredness.

Serious or Rare Side Effects

• Severe neutropenia with fever: risk of infection.
• Pulmonary toxicity: shortness of breath or cough.
• Severe allergic reactions: rash, swelling, or anaphylaxis.
• Liver enzyme elevation: potential hepatic injury.
• Peripheral neuropathy: tingling or numbness in extremities.
• Thrombocytopenia: low platelet count leading to bleeding.

Before initiating therapy with Vinorelbine, clinicians should consider several safety measures.

• Monitor blood counts: perform regular CBC to detect neutropenia.
• Assess hepatic function: check liver enzymes prior to each cycle.
• Evaluate renal function: adjust use if creatinine clearance is impaired.
• Avoid in patients with known hypersensitivity to Vinca alkaloids.
• Use effective contraception: prevent pregnancy during treatment.
• Store at room temperature: keep in original packaging, protect from moisture and direct sunlight.

Vinorelbine can interact with other medicines, influencing its efficacy or toxicity.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole): increase vinorelbine exposure.
• Strong CYP3A4 inducers (e.g., rifampin): reduce therapeutic levels.
• Concurrent myelosuppressive agents: heighten risk of severe bone‑marrow suppression.
• Drugs that prolong QT interval: may increase cardiac risk.
• Monoclonal antibodies targeting the same pathway: unclear additive effects.

Moderate Interactions (Monitor Closely)

• Moderate CYP3A4 inhibitors (e.g., erythromycin): may modestly raise levels.
• NSAIDs: can exacerbate gastrointestinal irritation.
• Warfarin: potential for altered anticoagulation control.
• Antifungal azoles (e.g., fluconazole): may require dose adjustment.
• Herbal supplements containing St. John’s wort: possible reduction in efficacy.